Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has acquired Icagen by merging its wholly owned subsidiary, Eclipse into Icagen, following which Icagen has become a wholly-owned subsidiary of Pfizer.
Subscribe to our email newsletter
Icagen is now part of Pfizer’s Worldwide Research and Development organization, and will be integrated into Neusentis, Pfizer’s Research Unit which includes Pain, Sensory Disorders and Regenerative Medicine.
Pfizer senior vice president Ruth McKerna said Icagen is known for its expertise in pain research.
"Their understanding of ion channel mechanisms will enhance our ability to develop novel drugs for the treatment of pain and related disorders," McKerna added.